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Abstract 
Aims 
To compare incidence of OSA in patients with and without type 2 diabetes and to investigate 
risk factors for OSA in patients with type 2 diabetes. 
Methods 
A retrospective cohort study was carried out to compare OSA incidence between adult 
patients with and without type 2 diabetes matched for age, sex and body mass index (BMI). 
Patients with a prevalent OSA diagnosis were excluded. The study cohort was derived from 
The Health Improvement Network (THIN), a UK primary care database, from 01/01/2005 to 
31/12/2017 
Results 
3110 (0.88%) and 5968 (0.46%) incident OSA cases were identified in the 360,250 exposed 
and 1,296,489 unexposed patient cohorts respectively. Adjusted incidence rate ratio (aIRR) of 
OSA in patients with type 2 diabetes compared to those without was 1.48 (95% CI 1.42-1.55; 
p<0.001).  
In a multivariate regression analysis of patients with type 2 diabetes, diabetes-related foot 
disease (1.23 (1.06-1.42); p=0.005), being prescribed insulin in the last 60 days (1.58 (1.42-
1.75); <0.001), male sex (aIRR 2.27 (2.09-2.46); p<0.001), being overweight (2.02 (1.54-
2.64); p<0.001) or obese (8.29 (6.42-10.69); p<0.001),  heart failure (1.41 (1.18-1.70); 
p<0.001), ischaemic heart disease (1.22 (1.11-1.34); p<0.001), atrial fibrillation (1.23 (1.04-
1.46); p=0.015), hypertension (1.32 (1.23-1.43); p<0.001), and depression (1.75 (1.61-1.91); 
p<0.001) were significant predictors of OSA. 
Conclusions 
When considered alongside previous evidence, this study indicates that the association 
between type 2 diabetes and OSA is bi-directional. In addition to known predictors of OSA 
diabetes-related foot disease and insulin treatment were identified as risk factors in patients 
with type 2 diabetes.  
  
 
 
 
 
 
 
 
 
 
  
Introduction 
Obstructive sleep apnoea (OSA) is a common disorder characterised by repeated complete or 
partial upper airway obstructions during sleep, leading to recurrent oxygen desaturations, 
cyclical adverse changes in heart rate, blood pressure (BP) and sympathetic activity, and 
disruption to sleep architecture(1). As a result, OSA has been linked to multiple adverse 
outcomes including: road traffic accidents(2), reduced workplace productivity(3), 
cardiovascular disease(4,5), hypertension(5,6), insulin resistance(7), increased mortality(8), and 
type 2 diabetes mellitus(9).   
Multiple epidemiological studies have indicated that OSA may be a risk factor for the 
development of type 2 diabetes independent of obesity and other confounders(9), possibly via 
the impact of recurrent hypoxaemia, inflammation, sympathetic activation and activation of 
the hypothalamic adrenal axis on insulin resistance and beta cell function(10). In addition, 
multiple cross-sectional studies have shown a high prevalence of undiagnosed OSA in 
patients with type 2 diabetes (24-86%)(11,12). Furthermore, cross-sectional and cohort studies 
have shown that OSA is associated with worse glycaemic control in patients with type 2 
diabetes(11-13) and with diabetes-related vascular complications(14-17). Hence, it is important to 
understand the complex relationships between OSA and type 2 diabetes, as OSA might be 
considered a modifiable risk factor for type 2 diabetes development and adverse outcomes in 
these patients(18). 
However, the potential role for type 2 diabetes as a risk factor for OSA has been less well 
examined. The relationship between OSA and type 2 diabetes is plausibly bi-directional. 
Type 2 diabetes might lead to the development of OSA due to the impact of insulin resistance 
and autonomic dysfunction on upper airways stability(19-21), as well as the increase in weight 
associated with some type 2 diabetes treatments. Hence, there is a need to examine the impact 
of type 2 diabetes on incident OSA. In addition, it is important to identify predictors of OSA 
in patients with type 2 diabetes to aid screening strategies. 
The primary aim of our study was to evaluate the role of type 2 diabetes as a risk factor for 
incident OSA using a matched controlled population-based retrospective cohort study. The 
secondary aim was to identify predictors of incident OSA in patients with type 2 diabetes. 
Methods 
Study design 
An age-, sex- and body mass index (BMI)-matched controlled retrospective cohort study 
from 01/01/2005 to 31/12/2017. 
Data source 
Data was extracted from The Health Improvement Network (THIN), an electronic primary 
care records database that contains anonymised medical records of over 15 million patients 
from 787 practices in the UK. The database is generalizable to the UK population. It consists 
of coded information on patient demographics, symptoms and diagnoses, drug prescriptions, 
consultations, diagnostic tests and their results. THIN is particularly suitable for analysing 
long-term health outcomes as GPs routinely collect and coordinate the patient’s data(22). 
THIN has been extensively used previously to study metabolic outcomes(23,24) and to study 
type 2 diabetes and OSA(25).  
Population 
To ensure high quality data, general practices were eligible for inclusion in the study from the 
latest of: 12 months after reporting acceptable mortality rates, 12 months after starting to use 
electronic medical records, and the study start date (01/01/2005). Adult patients aged 16 
years and above registered for at least 12 months with any of the eligible general practices 
prior to study entry formed the source population.  
Exposed cohort 
The exposed cohort consisted of adult patients with type 2 diabetes. Type 2 diabetes 
diagnosis was ascertained by the presence of any type 2 diabetes clinical (Read) code 
(Supplementary Table 1A) in the patient’s medical record and the absence of any record of 
type 1 diabetes. The Read code list used to define exposure has previously been used to study 
type 2 diabetes(26). In the primary analysis, all patients (prevalent and incident) with a type 2 
diabetes diagnosis were included. A sensitivity analysis including only patients with incident 
type 2 diabetes (newly diagnosed during the study period) was carried out to explore any 
effect of survival bias.  
Unexposed cohort  
For every exposed patient, up to 4 controls were randomly selected from an age-, sex- and 
BMI-matched pool of eligible patients without a record of type 2 diabetes at any time point 
before or during the study period. Age and BMI were matched to within 1 year and 2 kg/m2 
respectively.  
Follow-up period 
A 15-month latency period was used for all patients. For patients with incident type 2 
diabetes, index date was 15 months after the date of diagnosis; for patients with prevalent 
type 2 diabetes, index date was 15 months after the date the patient became eligible for 
inclusion. The 15-month interval was introduced to: 1) ensure that at baseline all predictors 
determining the risk of OSA in patients with diabetes were recorded, as the Quality and 
Outcomes Framework (QOF) ensures these are captured within a 15-month period; 2) limit 
the possibility of silent OSA preceding type 2 diabetes being misclassified as incident OSA. 
The unexposed patients were assigned the same index date as their corresponding exposed 
patient to avoid immortal time bias(27). Patients with type 2 diabetes and controls were 
followed from the index date until the earliest of the following end points: outcome (OSA) 
date, death date, date patient left practice, date the practice ceased contributing to the 
database, and study end date (31/12/2017).  
Outcomes 
OSA was identified by a record of any relevant clinical code (Supplementary Table 1B). 
Analysis 
Poisson regression was used to calculate crude incidence rate ratios (IRR) and adjusted 
incidence rate ratios (aIRR), together with their corresponding 95%CIs, 1) comparing 
incidence of OSA in patients with and without type 2 diabetes; and 2) in an analysis restricted 
to patients with type 2 diabetes to explore possible risk factors that may predict incidence of 
OSA. Patients with a record of the outcome at baseline were excluded for these analyses. 
Further exploratory analysis comparing the incidence of OSA between patients with and 
without type 2 diabetes was performed in subgroups of patients stratified by age, sex, BMI 
and the presence or absence of comorbid conditions including composite cardiovascular 
diseases (CVD) composed of heart failure, ischaemic heart disease, stroke/TIA, atrial fibrillation and 
hypertension, and composite mental health conditions (anxiety and depression). 
To evaluate any possible impact of surveillance bias and unobserved confounders on the 
outcome (OSA), in the same cohort we estimated the adjusted IRR of chronic obstructive 
pulmonary disease (COPD), a negative control outcome that has symptoms that overlap with 
those of diabetes (sleep disturbance and fatigue). 
A further sensitivity analysis was carried out restricting outcomes to those specifically 
recorded as obstructive-type sleep apnoea (Read code Fy03.11 or H5B0.00) to ensure the 
exclusion of central sleep apnoea outcomes. 
Study variables 
Covariates for the study were selected based on biological plausibility and previous literature. 
All regression models were adjusted for age, sex, BMI, deprivation quintile, smoking status 
and ethnicity. BMI recorded closest to the index date was categorized as <25 kg/m2, 25-30 
kg/m2 (overweight) and ≥30 kg/m2 (obese). Implausible BMI values below 14 and above 75 
were considered missing. Social deprivation was categorized as quintiles based on Townsend 
score(28). Smoking status was categorised as non-smoker, ex-smoker and smoker. Missing 
values for BMI, Townsend deprivation quintile and smoking status were treated as a separate 
missing category. 
In the model identifying risk factors for OSA among patients with type 2 diabetes, further 
diabetes-related covariates recorded within the 15-month period prior to index date were 
taken into consideration; these included: ethnicity, HbA1c category, eGFR category, record 
of hypoglycaemic attack, diagnosis of foot disease, retinopathy, cardiovascular disease (heart 
failure, ischaemic heart disease, stroke/TIA, atrial fibrillation and hypertension), mental 
health conditions, and prescription of lipid-lowering drugs and insulin within 60 days prior to 
the index date. Implausible HbA1c values above 20 mmol/mol and eGFR above 200 
mL/min/1.73m2 were considered missing. Lipid-lowering drugs were used as a proxy 
measure for hypercholesterolaemia, and insulin as an indicator of diabetes severity.  
eGFR was calculated using the CKD-EPI equation from the serum creatinine values and 
ethnicity data (where available). HbA1c was categorized as ≤6.5% (47.50 mmol/mol), 6.5-
7.5% (47.51-58.50 mmol/mol), 7.5-8.5% (58.51-69.40 mmol/mol) and >8.5% (69.40 
mmol/mol); calculated eGFR was categorized as ≥90 mL/min/1.73m2 (stage 1 chronic kidney 
disease), 60-89 mL/min/1.73m2 (stage 2), 30-59 mL/min/1.73m2 (stage 3) and <30 
mL/min/1.73m2 (stage 4 and 5). Retinopathy was considered as a composite of sight-
threatening retinopathy graded as R2 (pre-proliferative), R3 (proliferative) or M1 
(maculopathy), vision loss and utilization of medical procedures such as laser and vitreous 
injections. Diabetes-related foot disease was a composite of lower limb amputation, 
gangrene, foot ulcer, Charcot foot, peripheral vascular disease and peripheral neuropathy. 
The covariates were identified by clinical codes indicating the condition, or treatments 
performed specific to the condition. All covariates are included in disease registers which 
general practices are expected to maintain as per the QOF(29).  
Analyses were performed in Stata IC version 14. Two-sided p-values were obtained and p-
value <0.05 was considered as statistically significant.   
The results of this study are reported in line with RECORD guidelines (Supplementary Table 
2). 
Results 
Baseline characteristics 
360,250 eligible patients with type 2 diabetes were identified; these patients were matched for 
age, sex and BMI to 1,296,489 patients without type 2 diabetes (unexposed/control cohort). 
Baseline characteristics are reported in Table 1. The matching parameters age and sex were 
similar between the exposed and unexposed groups (mean (SD) age 64.9 (13.3) vs 64.6 (13.6) 
years; male sex 55.5% vs 54.2%). Patients in the exposed cohort had a slightly higher mean 
BMI compared to controls (31.0 (6.5) vs 29.8 (5.8)), but the difference was within the 
matching range (±2 kg/m2). Compared to controls, patients with diabetes were more deprived 
(13.7% vs 9.9% were in the most deprived Townsend quintile), and were more likely to be of 
south Asian ethnicity (3.8% vs 0.9%). Patients with diabetes also had higher levels of 
cardiovascular diseases, including heart failure (4.8% vs 2.5%), ischaemic heart disease 
(19.1% vs 11.4%) and stroke/TIA (8.8% vs 5.9%) and greater usage of lipid-lowering drugs 
(63.7% vs 23.6%). Prevalent OSA at baseline (recorded up to 15 months after index date) 
was higher among exposed compared to unexposed patients (1.8% vs 0.9%); these patients 
were excluded in subsequent analyses.  
Type 2 diabetes and incidence of OSA 
3110 (0.88%) patients with diabetes and 5968 (0.46%) controls developed OSA during the 
follow-up period (Table 2). Crude incidence rate of OSA among patients with and without 
diabetes was 1.76 and 1.00 per 1000 person-years; IRR 1.76 (95%CI 1.69-1.84; p<0.001). 
After adjustment for potential confounders including age, sex, BMI, Townsend deprivation 
quintile, smoking status and ethnicity, the association remained statistically significant: aIRR 
1.48 (95%CI 1.42-1.55; p<0.001). Further adjustment for composite CVD at baseline slightly 
attenuated the effect: aIRR 1.36 (95%CI 1.30-1.42; p<0.001). The association remained 
similar in a further sensitivity analysis including only patients with incident type 2 diabetes 
and their corresponding controls (Supplementary table 3A): aIRR 1.41 (95%CI 1.30-1.51; 
p<0.001) (Table 2). 
Subgroup and sensitivity analyses 
With the exception of patients aged 16-29 years, in all of the age- and BMI-stratified cohorts 
there was a significant increase in OSA incidence in patients with type 2 diabetes compared 
to patients without (Figure 1). Risk of OSA was increased in both sexes but the association 
between diabetes and OSA was stronger in women (aIRR: 1.39 (95%CI 1.32-1.46) and 1.76 
(95%CI 1.62-1.91); in men and women respectively). Irrespective of the presence or absence 
of comorbid conditions, there was a statistically significant increase in OSA incidence in 
patients with type 2 diabetes. 
In the analysis restricting outcomes to those explicitly coded as obstructive type sleep apnoea, 
there was an increase in the observed effect size: (aIRR 1.62 (95%CI 1.52-1.73); p<0.001) 
(Supplementary Table 3B). 
Impact of surveillance bias 
In the analysis considering COPD as an outcome, there was no significant increase in the 
incidence of COPD in patients with type 2 diabetes compared to patients without type 2 
diabetes after adjusting for age, sex, BMI, Townsend deprivation quintile, smoking status and 
ethnicity (aIRR 1.03 (95%CI 0.99-1.08); p=0.112). 
Risk factors for OSA among patients with type 2 diabetes  
Among the 20 risk factors considered, male sex (aIRR 2.27 (95%CI 2.09-2.46); p<0.001), 
being overweight (2.02 (1.54-2.64); p<0.001) or obese (8.29 (6.42-10.69); p<0.001), being a 
previous smoker (1.13 (1.04-1.22); p=0.004), diabetes-related foot disease (1.23 (1.06-1.42); 
p=0.005), heart failure (1.41 (1.18-1.70); p<0.001), ischaemic heart disease (1.22 (1.11-1.34); 
p<0.001), atrial fibrillation (1.23 (1.04-1.46); p=0.015), hypertension (1.32 (1.23-1.43); 
p<0.001), depression (1.75 (1.61-1.91); p<0.001) and insulin prescription (1.58 (1.42-1.75); 
p<0.001) were significantly predictive of incident OSA in patients with type 2 diabetes 
(Table 3).  
In a sensitivity analysis including only incident/newly diagnosed patients with type 2 
diabetes, the results remained similar except for four of the risk factors considered: 
hypoglycaemic event became statistically significant as a predictor of OSA (aIRR 2.06 
(95%CI 1.26-3.39); p=0.004), while being a previous smoker, atrial fibrillation and 
prescription of insulin became non-significant as predictors in the model (Supplementary 
Table 3C).  
Discussion 
This study showed that patients with type 2 diabetes have an almost 50% increase in risk of 
developing OSA compared to patients without type 2 diabetes, independent of potential 
confounders and traditional OSA risk factors. In addition, our study identified predictors of 
incident OSA in patients with type 2 diabetes including male sex, obesity, CVD, diabetes-
related foot disease, and depression. This is the first study to identify predictors of incident 
OSA in patients with type 2 diabetes and to examine the links between type 2 diabetes and 
incident OSA in a European population.  
Previous literature has shown that OSA is an independent risk factor for the development of 
type 2 diabetes; our results suggest that this relationship is bi-directional, as patients with 
type 2 diabetes were also at increased risk of developing OSA, despite excluding patients in 
whom OSA was diagnosed up to 15 months after type 2 diabetes diagnosis. While many 
studies have examined the impact of OSA on type 2 diabetes, there is little evidence 
regarding the impact of type 2 diabetes on OSA. One longitudinal cohort study of 1780 men 
and 1785 women, the Data from an Epidemiologic Study on the Insulin Resistance Syndrome 
(D.E.S.I.R.) study, found that fasting insulin (OR 1.31, 95%CI 1.13-1.51) and homeostasis 
model assessment of insulin resistance (HOMA-IR) (OR 1.24, 95%CI 1.09-1.4) were 
predictors of incident “witnessed apnoea” over a 6-year period independent of obesity (19). 
This result suggests that dysglycaemia and insulin resistance might lead to the development 
of OSA, but there was no formal assessment of OSA in this study as the diagnosis was based 
on self-reported witnessed apnoeas during sleep. A more recent analysis of the combined 
population of 146,519 participants from the Nurses’ Health Study (NHS; 2002–2012), 
Nurses’ Health Study II (NHSII; 1995–2013), and Health Professionals Follow-up Study 
(HPFS; 1996–2012) by Huang et al showed that patients with type 2 diabetes were at 
increased risk of developing OSA compared to patients without diabetes (HR 1.53; 95%CI 
1.32-1.77) which was attenuated after adjustment for obesity (HR 1.08; 95%CI 1.00, 1.16)(30). 
Consistent with our findings, Huang et al also found that insulin-treated patients with type 2 
diabetes were at increased risk of OSA compared to patients without diabetes after 
adjustment for obesity (HR 1.43; 95%CI 1.11, 1.83), particularly among women (HR 1.60; 
95%CI 1.34, 1.89). Our study differs from the Huang et al study in multiple aspects. The 
study of Huang et al included patients who were free of CVD at baseline while CVD was 
common in our study population, suggesting that we have a population with more advanced 
disease. The diagnosis of OSA in the study by Huang et al was based on self-reporting while 
in our study the OSA diagnosis was based on clinical codes indicating physician diagnosis. 
The design of the two studies also differed as our study matched for major OSA risk factors 
between patients with and without type 2 diabetes. Finally, the relationship between type 2 
diabetes and incident OSA became non-significant when adjusting for obesity in the Huang et 
al study, while our study showed that type 2 diabetes predicted incident OSA independent of 
obesity and despite adjustment for a wider range of potential confounders than those 
considered in the study by Huang et al. Despite these differences, our findings together with 
those of the above-mentioned studies strongly suggest that the relationship between type 2 
diabetes and OSA is bi-directional. 
The lack of a linear relationship between age and OSA incidence in patients with type 2 
diabetes in this study is interesting, and possibly explained by the fact that the average age of 
our study patients with type 2 diabetes was approximately 65 years old, and several previous 
studies have shown that the age-related increase in prevalence occurred before age 65,(31) a 
finding that is reflected in our analysis. 
In age-, sex- and BMI-stratified subgroup analyses, increased incidence of OSA was 
observed in patients with type 2 diabetes in all of the subgroups. There was a greater effect 
size in women compared to men, which concurs with previous evidence suggesting an 
increased susceptibility of women with type 2 diabetes to adverse health outcomes(32). The 
observed effect sizes were slightly higher in patients with comorbid conditions, but this was 
not statistically significant. In a sensitivity analysis including baseline cardiovascular 
conditions as a covariate, there was a slight reduction in the effect size, indicating that CVD 
may be a potential effect modifier in the association between type 2 diabetes and incident 
OSA.  
To explore any impact of surveillance bias, we performed an exploratory analysis considering 
COPD as the outcome instead of OSA. COPD was used as increased screening rates and 
surveillance, and therefore detection, might occur in patients with type 2 diabetes as the two 
conditions have common symptoms, including sleep disturbance and fatigue. However, there 
was no statistically significant increase in incident COPD in patients with type 2 diabetes, 
suggesting that the observed increase in incident OSA reflects a true difference. While the 
impact of OSA on incident type 2 diabetes is probably related to increased oxidative stress, 
inflammation, sympathetic activation and HPA activation(33), type 2 diabetes might lead to 
the development of OSA via multiple mechanisms including: weight gain mediated by 
medications such as sulfonylureas, glitazones and insulin, or by hypoglycaemia decreased 
physical activity; co-morbidities like diabetic neuropathy; or changes related to lung volumes 
(10). Our study supports some of these plausible mechanisms by showing obesity, diabetes-
related foot disease (which encompasses neuropathy) and insulin treatment were predictors of 
incident OSA in patients with type 2 diabetes. However, the relationship between type 2 
diabetes and OSA persisted after adjustment for a wide range of potential confounders. 
Interestingly, in our study depression and CVD were predictors of incident OSA, which 
aligns with previous studies showing high prevalence of OSA in these conditions(34,35). On the 
other hand, some traditional OSA risk factors, such as age, ethnicity and smoking, were not 
identified as predictors of OSA in our study. This could potentially be due to the multiple risk 
factors considered in the model, where weak effects were obscured, or the fact that our study 
population included only patients with type 2 diabetes rather than the general population. 
Due to the high prevalence of OSA in patients with type 2 diabetes, the International Diabetes 
Federation (IDF) issued a statement suggesting that all patients with type 2 diabetes should be 
screened for OSA(36). However, due to the large number of patients with type 2 diabetes and 
the lack of easily available screening methods beyond questionnaires, this IDF statement has 
not been widely followed(37). Our study supports the IDF statement by identifying high risk 
groups within patients with type 2 diabetes who are at particularly high risk of developing 
OSA, including men, and patients with CVD, depression, diabetes-related foot disease, 
patients experiencing hypoglycaemia, and those treated with insulin. However, it must be 
noted that despite the IDF statement, the proportion of patients with type 2 diabetes who are 
willing to be tested for OSA might be low(38) and the impact of CPAP treatment on diabetes-
related outcomes from RCTs remains uncertain or lacking (except with regard to blood 
pressure)(39-41). Nonetheless, in general population studies, CPAP has been shown to improve 
quality of life and sleepiness in patients with and without diabetes(42,43). 
OSA in patients with type 2 diabetes has been linked to worse glycaemic control, higher BP, 
CVD and microvascular complications(11,16,17,44,45). In all these studies, it was not clear 
whether the diagnosis of OSA preceded or followed the diagnosis of type 2 diabetes. In view 
of our data showing that patients with type 2 diabetes are at increased risk of developing 
OSA, it would be of interest to examine whether the impact of OSA in these patients differs 
depending on whether OSA developed before or after the diagnosis of type 2 diabetes. 
Strengths and limitations 
This study included a large sample size from the THIN database, which is generalizable to 
the UK population. Routinely collected data may be subject to potential biases resulting from 
incorrect, inconsistent or incomplete coding of conditions. However, the conditions 
considered in this study are part of the Quality and Outcomes Framework and recording 
quality is therefore expected to be high. The prevalence of major conditions and death rates, 
adjusted for patient demographics, in THIN are similar to national rates(46). 
Ethnicity is not well recorded in THIN; as a result, ethnicity data was not available for all 
patients in the sample. In addition, adiposity measures such as neck- and waist-circumference 
are poorly recorded in primary care and, hence, were not included as covariates in our 
analysis. It is possible that the observed association between diabetes and OSA was driven by 
these measures of central obesity, which are common to both diabetes and OSA. Nonetheless 
our findings were independent of BMI, which is commonly used in large epidemiological 
studies, and usually correlates with these measures of adiposity. The prevalence of OSA 
observed in patients at baseline was lower than what has been reported in other studies(12,13,47) 
as routinely collected primary care-based OSA diagnosis is subject to under-diagnosis, under-
recording and differences in temporal and inter-clinic diagnostic criteria. We introduced a 15-
month latency period at the start of the study in order to limit the possibility of silent OSA 
preceding the diabetes diagnosis being classified as incident OSA. However, we cannot 
completely rule out the possibility that patients with undiagnosed OSA were included in the 
study, as it was not possible to investigate patients for OSA at baseline. It is also possible that 
the effect of increased surveillance might have had an impact on the OSA detection rate in 
patients with diabetes, particularly since symptoms of OSA and diabetes might overlap (such 
as fatigue and sleep disturbance). The exploratory analysis for COPD reported above 
suggests the impact of surveillance bias due to increased contact with health care 
practitioners is likely to be small, however, surveillance bias due to differential screening and 
detection rates in the exposed/unexposed groups cannot be completely ruled out. 
Although we cannot determine the methods used to diagnose OSA in our study, patients in 
the UK are usually diagnosed with OSA following an assessment in a sleep clinic/centre as 
described in the National Institute of Clinical Excellence and the British Lung Foundation 
guidance(48). Nonetheless, the methods (for example, oximetry vs polygraphy vs 
polysomnography) and criteria (ODI vs AHI and different cut offs of AHI or ODI) used to 
diagnose OSA could vary between different sleep centres. 
Conclusions 
Patients with type 2 diabetes are at increased risk of developing OSA; the association 
remained significant after adjusting for potential confounders. In addition to known 
predictors of OSA, diabetes-related foot disease and insulin treatment were identified as risk 
factors for OSA in patients with type 2 diabetes. Clinicians should consider testing for OSA 
in patients with type 2 diabetes, particularly in men, and patients with high BMI, diabetes-
related foot disease, CVD, hypertension and depression, and those prescribed insulin, as these 
were shown to be independent risk factors for incident OSA. When taken together with 
previous evidence, this study indicates that the association between type 2 diabetes and OSA 
is bi-directional. Further research is required to investigate whether the sequence in which the 
two diseases develop has an impact on outcomes in patients with type 2 diabetes and OSA. 
 
Figure legend 
Figure 1. Forest plot showing adjusted incidence rate ratios (aIRR) for OSA in patients with 
type 2 diabetes compared to patients without diabetes in age-, sex-, BMI- and comborbidity-
stratified patient subgroups. 
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Table 1. Baseline patient characteristics for type 2 diabetes exposed and unexposed patients 
  Exposed Unexposed 
Population, n 360250 1296489 
Age years, mean (SD) 64.85 (13.28) 64.56 (13.63) 
Age categories, years, n (%)   16 – 29 2117 (0.59) 8373 (0.65) 
30 – 39 11095 (3.08) 43951 (3.39) 
40 – 49 38704 (10.74) 149940 (11.57) 
50 – 59 74341 (20.64) 271837 (20.97) 
60 – 69 99805 (27.70) 346252 (26.71) 
70 – max 134188 (37.25) 476136 (36.73) 
Sex, n (%)   Men 199941 (55.50) 702927 (54.22) 
Women 160309 (44.50) 593562 (45.78) 
BMI (kg/m2), mean (SD) 31.00 (6.47) 29.83 (5.80) 
BMI categories, n (%)   Under/Normal weight (<25 kg/m2) 54047 (15.00) 234404 (18.08) 
Overweight (25-30 kg/m2) 118393 (32.86) 489719 (37.77) 
Obese (≥30 kg/m2) 179959 (49.95) 542588 (41.85) 
Missing 7851 (2.18) 29778 (2.30) 
Townsend, n (%)   
    1 64764 (17.98) 299727 (23.12) 
    2 64862 (18.00) 270123 (20.83) 
    3 68180 (18.93) 241708 (18.64) 
    4 65566 (18.20) 197086 (15.20) 
    5 49372 (13.70) 128651 (9.92) 
    Missing 47506 (13.19) 159194 (12.28) 
Smoker categories, n (%)   Non-smoker 174233 (48.36) 690164 (53.23) 
Previous smoker 129534 (35.96) 405090 (31.25) 
Smoker 55482 (15.40) 188833 (14.56) 
Missing 1001 (0.28) 12402 (0.96) 
Ethnicity, n (%)   Caucasian  151519 (42.06) 533954 (41.18) 
Black Afro-Caribbean 5858 (1.63) 10272 (0.79) 
Chinese 2432 (0.68) 3990 (0.31) 
South Asian 13663 (3.79) 11351 (0.88) 
Mixed Race 1199 (0.33) 2432 (0.19) 
Missing  185579 (51.51) 734490 (56.65) 
eGFR, median (IQR) 76.5 (60.6-91.3) 74.3 (61.2-87.2) 
eGFR category   
    >90 mL/min/1.73m2 (Stage 1)  97438 (27.05) 208516 (16.08) 
    60-90 mL/min/1.73m2 (Stage 2) 178998 (49.69) 599575 (46.25) 
    30-59 mL/min/1.73m2 (Stage 3) 74006 (20.54) 207151 (15.98) 
    <30 mL/min/1.73m2 (Stage 4+5) 7384 (2.05) 13083 (1.01) 
    Missing 2424 (0.67) 268164 (20.68) 
Baseline comorbidities, n (%)   Cardiovascular diseases   
    Heart failure 17304 (4.80) 32924 (2.54) 
    Ischaemic heart disease 68908 (19.13) 147418 (11.37) 
    Stroke/TIA 31687 (8.80) 76128 (5.87) 
    Atrial fibrillation  25174 (6.99) 65688 (5.07) 
    Hypertension 213479 (59.26) 489418 (37.75) 
Mental health conditions   Anxiety 57756 (16.03) 200706 (15.48) 
Depression 75642 (21.00) 241215 (18.61) 
Baseline drug use (within 60 days of index), n (%)   
     Lipid-lowering drugs 229287 (63.65) 305443 (23.56) 
Outcome at baseline   
OSA* 6567 (1.82) 11682 (0.90) 
Diabetes-related variables†   
HbA1c (mmol/mol), median (IQR) 51.9 (45.0-60.6)  
HbA1c category †   
     ≤6.5% (47.500 mmol/mol) 98835 (27.44)  
     6.5-7.5% (47.501-58.500 mmol/mol) 114821 (31.87)  
     7.5-8.5% (58.501-69.400 mmol/mol) 41049 (11.39)  
     ≥ 8.5% (69.401 mmol/mol)  43093 (11.96)  
    Missing  62452 (17.34)  
Concurrent conditions within 15 months of diabetes diagnosis   
    Foot Disease  22305 (6.20)  
    Retinopathy/Low vision/Blindness 16911 (4.69)  
    Hypoglycaemic event 7555 (2.10)  
Baseline drug use(within 60 days of index), n (%)   
     Insulin 26877 (7.46)  
*These patients were excluded from subsequent analysis.†Diabetes-related variables are reported only 
for the exposed cohort as they are not applicable to the unexposed cohort.  
 
 
 
Table 2. Crude and adjusted incidence rate ratios for OSA in patients with type 2 diabetes 
compared to those without type 2 diabetes 
 Primary Cohort Incident Cohort 
  Exposed Unexposed Exposed Unexposed 
Outcome events, n (%) 3110 (0.88) 5968 (0.46) 1238 (0.82) 2698 (0.48) 
Person-years 1763982 5963919 646356 2245189 
Crude IR per 1000 person-years 1.76 1.00 1.92 1.20 
Follow-up years, median (IQR) 4.40 (2.06-7.60) 
3.94 (1.80-
7.07) 3.77 (1.84-6.39) 3.43 (1.62-5.94) 
Unadjusted IRR (95% CI) 1.76 (1.69-1.84); p<0.001 1.59 (1.47-1.72); p<0.001 
Partially adjusted IRR* (95% CI) 1.48 (1.42-1.55); p<0.001 1.41 (1.32-1.51); p<0.001 
Fully adjusted IRR* (95% CI) 1.36 (1.30-1.42); p<0.001 1.31 (1.22-1.40); p<0.001 
*Adjusted for age category, sex, BMI category, Townsend deprivation quintile, smoking status and 
ethnicity. 
† Adjusted for age category, sex, BMI category, Townsend deprivation quintile, smoking status, 
ethnicity and baseline cardiovascular conditions (heart failure, ischemic heart disease, stroke/TIA, 
atrial fibrillation and hypertension). 
 
 
 
Table 3. Predictors of OSA incidence in patients with type 2 diabetes  (n=353683)  
Risk factors aIRR (95% CI); p value* 
Age categories, years  16 – 29 Ref 
30 – 39 1.70 (0.92-3.14); 0.092 
40 – 49 1.71 (0.94-3.11); 0.080 
50 – 59 1.72 (0.95-3.13); 0.075 
60 – 69 1.13 (0.62-2.05); 0.700 
> 70 0.44 (0.24-0.81); 0.009 
Sex  Women Ref 
Men 2.27 (2.09-2.46); <0.001 
BMI categories   
Underweight/normal weight (<25 kg/m2) Ref 
Overweight (25-30 kg/m2) 2.02 (1.54-2.64); <0.001 
Obese (≥30 kg/m2) 8.29 (6.42-10.69); <0.001 
Missing 3.68 (2.31-5.86); <0.001 
Townsend  1 Ref 
2 0.92 (0.82-1.04); 0.202 
3 0.91 (0.81-1.03); 0.129 
4 0.94 (0.84-1.06); 0.303 
5 0.91 (0.80-1.03); 0.152 
Missing 0.97 (0.86-1.11); 0.681 
Smoker categories  Non-smoker Ref 
Previous smoker 1.13 (1.04-1.22); 0.004 
Smoker 1.11 (1.00-1.22); 0.051 
Missing 0.89 (0.40-1.99); 0.775 
Ethnicity  Caucasian Ref 
Black Afro-Caribbean 0.81 (0.57-1.16); 0.252 
Chinese 0.67 (0.35-1.30); 0.238 
South Asian 1.21 (0.98-1.49); 0.080 
Mixed race 0.98 (0.49-1.97); 0.965 
Missing 1.01 (0.93-1.08); 0.874 
eGFR category  
    >90 mL/min/1.73m2 (Stage 1)  Ref 
    60-90 mL/min/1.73m2 (Stage 2) 0.95 (0.87-1.03); 0.223 
    30-59 mL/min/1.73m2 (Stage 3) 1.00 (0.88-1.14); 0.987 
    <30 mL/min/1.73m2 (Stage 4+5) 0.93 (0.64-1.36); 0.726 
    Missing 0.51 (0.26-0.99); 0.046 
Concurrent conditions within 15 months of diabetes diagnosis   Cardiovascular diseases  
Heart failure  1.41 (1.18-1.70); <0.001 
Ischaemic heart disease  1.22 (1.11-1.34); <0.001 
Stroke/TIA 0.92 (0.78-1.07); 0.284 
Atrial fibrillation 1.23 (1.04-1.46); 0.015 
Hypertension 1.32 (1.23-1.43); <0.001 
Mental health conditions  
Anxiety  1.07 (0.97-1.18); 0.179 
Depression 1.75 (1.61-1.91); <0.001 
Baseline drug use (within 60 days of index), n (%)  
Lipid-lowering drugs  1.05 (0.96-1.15); 0.296 
Diabetes-related variables  
HbA1c category   
≤6.5% (47.500 mmol/mol) Ref 
6.5-7.5% (47.501-58.500 mmol/mol) 0.90 (0.82-1.00); 0.043 
7.5-8.5% (58.501-69.400 mmol/mol) 1.00 (0.88-1.13); 0.977 
≥ 8.5% (69.401 mmol/mol)  0.98 (0.87-1.10); 0.742 
Missing  0.88 (0.78-0.98); 0.025 
Concurrent conditions within 15 months of diabetes diagnosis  
Foot Disease  1.23 (1.06-1.42); 0.005 
Retinopathy/Low vision/Blindness 0.95 (0.79-1.13); 0.556 
Hypoglycaemic event 1.06 (0.83-1.35); 0.656 
Baseline drug use (within 60 days of index), n (%)  
Insulin  1.58 (1.42-1.75); <0.001 
*Adjusted for age, sex, BMI category, Townsend deprivation quintile, smoking status, ethnicity, 
HbA1c category, eGFR category, record of hypoglycaemic attack, diagnosis of foot disease, 
retinopathy, cardiovascular disease (heart failure, ischaemic heart disease, stroke/TIA, atrial 
fibrillation and hypertension), mental health conditions (anxiety and depression), and prescription of 
lipid lowering drugs and insulin within 60 days of the index date. 
